Welcome to our dedicated page for Icecure Medical Ltd. SEC filings (Ticker: ICCM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
IceCure Medical Ltd. (Nasdaq: ICCM) is a foreign private issuer that files reports with the U.S. Securities and Exchange Commission (SEC) in connection with its liquid-nitrogen-based cryoablation systems for tumor destruction. On this page, you can review IceCure’s SEC filings, including current reports on Form 6-K that furnish press releases about regulatory milestones, clinical data, commercial progress, and corporate actions.
IceCure’s Form 6-K filings often incorporate press releases by reference into its registration statements on Form F-3 and Form S-8. These filings cover topics such as U.S. Food and Drug Administration (FDA) marketing authorization for the ProSense® Cryoablation System in low-risk breast cancer for women aged 70 and above, regulatory approvals for ProSense® in Switzerland and other markets, notices of patent allowance for technologies like cryogen flow control related to the next-generation XSense™ system, and financial and operational results for specified reporting periods.
Filings also document corporate developments, including changes in management roles and Nasdaq notifications regarding minimum bid price compliance. By reviewing these documents, investors can see how IceCure describes its minimally invasive cryoablation technology, its primary focus areas in breast, kidney, bone, and lung cancer, and the regulatory and commercial steps it reports taking to expand use of ProSense® and XSense™.
Stock Titan’s SEC filings page presents IceCure’s submissions as they are made available on EDGAR and enhances accessibility with AI-powered summaries. These summaries are designed to highlight key points from lengthy documents, such as the nature of a regulatory authorization, the scope of a patent allowance, or the main elements of a financial update. Users can quickly identify filings related to clinical milestones, regulatory approvals, capital markets activity, and other material events disclosed by IceCure Medical Ltd.
IceCure Medical Ltd. is registering up to 16,000,000 Ordinary Shares for resale by selling shareholders, consisting of up to 8,000,000 shares issuable upon exercise of Series B warrants and up to 8,000,000 shares issuable upon exercise of Series C warrants. No Ordinary Shares are being sold by the company in this registration; the company will receive cash only if the Warrants are exercised. As of March 31, 2026, 81,180,045 Ordinary Shares were issued and outstanding.
The company is offering 8,000,000 Ordinary Shares in a registered direct offering at a combined purchase price of $0.50 per Ordinary Share together with privately placed Series B and Series C warrants.
The offering includes a concurrent private placement of up to 16,000,000 Warrants (8,000,000 Series B Warrants and 8,000,000 Series C Warrants) exercisable at $0.55 per share. Net proceeds are estimated at approximately $3.5 million, intended for working capital and general corporate purposes.
IceCure Medical Ltd. received an amended Schedule 13D from Epoch Partner Investments Limited and its sole director, Mr. Li Haixiang, updating their reporting on ownership and governance. The filing states they beneficially own approximately 45.8% of IceCure’s ordinary shares, based on 73,122,293 shares outstanding as of December 31, 2025.
The amendment primarily reflects that Mr. Li resigned from IceCure’s board of directors on March 17, 2026, and clarifies that Epoch directly holds the shares, while Mr. Li’s beneficial ownership arises from his role as Epoch’s sole director. The reporting persons disclose no share transactions in the past 60 days and no special arrangements regarding the securities.
IceCure Medical Ltd. entered into agreements with healthcare-focused institutional investors for a capital raise combining a registered direct offering and a concurrent private placement. The company agreed to sell 8,000,000 ordinary shares at $0.50 per share in a registered direct offering, for expected gross proceeds of about $4.0 million before fees and expenses.
Concurrently, IceCure will issue unregistered Series B warrants to purchase up to 8,000,000 ordinary shares and Series C warrants to purchase up to 8,000,000 ordinary shares, each with an exercise price of $0.55 per share. The Series B warrants will be exercisable immediately and expire five years after issuance, while the Series C warrants will be exercisable immediately and expire after one year. Net proceeds are currently intended for working capital and general corporate purposes, and closing is expected on or about March 27, 2026, subject to customary conditions.
IceCure Medical Ltd. director Malca Yonatan filed an initial statement of beneficial ownership on Form 3. The provided data shows no reported transactions or derivative positions and no specific share holdings listed, indicating this is a baseline regulatory disclosure of insider status rather than a trading event.
IceCure Medical Ltd. director Huang Yang filed an initial ownership report detailing equity holdings in the company. The filing shows 111,468 restricted stock units (RSUs) granted on May 15, 2025, with 41,800 vested and 69,668 unvested as of March 18, 2026.
Huang also holds several fully vested share options over ordinary shares, including 25,000 options at an exercise price of $1.70 per share expiring in December 2030 and 80,668 options at $3.64 per share expiring in January 2032, plus an additional option grant at $1.51 per share expiring in February 2033.
IceCure Medical Ltd. director Chan Vincent Chun Hung filed an initial Form 3, which is a required statement of beneficial ownership when someone becomes an insider such as a director or large shareholder. This filing reports no transactions and no share movements; it is purely an ownership disclosure record at this stage.
IceCure Medical Ltd. executive Tel-Tzure Tlalit Bussi, VP of BD & Global Marketing, reports her initial ownership position. As of March 18, 2026, she beneficially owns 170,629 ordinary shares and restricted share units. She also holds multiple share option grants over ordinary shares at exercise prices ranging from $0.92 to $5.78, with expirations between 2029 and 2034, many of which are fully vested.
IceCure Medical Ltd. Chief Operating Officer Levav Shay filed an initial ownership report showing direct holdings of 144,615 ordinary shares plus several option grants. These options cover 50,000 shares at an exercise price of $1.56, 385 shares at $5.78, 80,668 shares at $3.64, 4,084 shares at $2.84, 40,705 shares at $1.51, and 98,182 shares at $0.92, with expirations ranging from 2030 to 2034. Footnotes state that some grants are already fully vested, while others vest in quarterly installments. In addition, Shay has unvested restricted share units of 81,818, 43,416 and 19,381 units from awards dated July 2, 2024, November 5, 2025 and March 16, 2026, respectively, all unvested as of March 18, 2026.
IceCure Medical Ltd. director Sharon Levita filed an initial insider ownership report on Form 3. The provided data shows no reportable transactions or derivative positions included in this filing.